PLSE — Pulse Biosciences Cashflow Statement
0.000.00%
- $1.18bn
- $1.08bn
- 35
- 16
- 26
- 13
Annual cashflow statement for Pulse Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -49.9 | -63.7 | -58.5 | -42.2 | -53.6 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 10.2 | 14.6 | 13.9 | 7.19 | 13.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.2 | -6.2 | -3.72 | 0.768 | 2.47 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -35.4 | -54.1 | -47 | -33 | -36.3 |
| Capital Expenditures | -0.441 | -0.437 | -0.401 | -0.121 | -0.125 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 10.5 | 8 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 10 | 7.56 | -0.401 | -0.121 | -0.125 |
| Financing Cash Flow Items | — | -0.232 | 0 | -0.006 | -0.281 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 30.9 | 62.7 | 79.9 | 16.4 | 110 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.56 | 16.2 | 32.5 | -16.8 | 73.7 |